References
- Cohen J. Swine flu pandemic. What’s old is new: 1918 virus matches 2009 H1N1 strain. Science327(5973), 1563–1564 (2010).
- Guan Y, Poon LL, Cheung CY et al. H5N1 influenza: a protean pandemic threat. Proc. Natl Acad. Sci. USA101(21), 8156–8161 (2004).
- World Health Organization. WHO guidelines of the use of vaccines and antivirals during influenza pandemics. WHO, Geneva, Switzerland (2004).
- Stacy L. Biological Threat and Terrorism: Assessing the Science and Response Capabilities. Forum on Emerging Infections. National Academic Press, Washington, DC, USA, 176 (2002).
- Gaudioso J, Salerno RM. Science and government. Biosecurity and research: minimizing adverse impacts. Science305(5681), 180 (2004).
- Kim CU, Lew W, Williams MA et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J. Am. Chem. Soc.119(4), 681–690 (1997).
- Sy CL, Lee SS, Liu MT, Tsai HC, Chen YS. Rapid emergence of oseltamivir resistance. Emerg. Infect. Di.16(4), 723–725 (2010).
- Wensing AM, van Maarseveen NM, Nijhuis M. Fifteen years of HIV protease inhibitors: raising the barrier to resistance. Antiviral Res.85(1), 59–74 (2010).
- Crotty S, Maag D, Arnold JJ et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med.6(12), 1375–1379 (2000).
- Crotty S, Cameron C, Andino R. Ribavirin’s antiviral mechanism of action: lethal mutagenesis? J. Mol. Med.80(2), 86–95 (2002).
- Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve. Clin. J. Med.71(Suppl. 3), S17–S21 (2004).
- Beigel J, Bray M. Current and future antiviral therapy of severe seasonal and avian influenza. Antiviral Res.78(1), 91–102 (2008).
- Gowen BB, Wong MH, Jung KH et al.In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother.51(9), 3168–3176 (2007).
- Song JM, Seong BL. Tea catechins as a potential alternative anti-infectious agent. Expert Rev. Anti Infect. Ther.5(3), 497–506 (2007).
- Wolf MC, Freiberg AN, Zhang T et al. A broad-spectrum antiviral targeting entry of enveloped viruses. Proc. Natl Acad. Sci. USA107(7), 3157–3162 (2010).
- Jouvenet N, Neil SJ, Zhadina M et al. Broad-spectrum inhibition of retroviral and filoviral particle release by tetherin. J. Virol.83(4), 1837–1844 (2009).
- Lara HH, Ayala-Nunez NV, Ixtepan-Turrent L, Rodriguez-Padilla C. Mode of antiviral action of silver nanoparticles against HIV-1. J. Nanobiotechnology8, 1 (2010).
- O’Keefe BR, Vojdani F, Buffa V et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc. Natl Acad. Sci. USA106(15), 6099–6104 (2009).
- O’Keefe BR, Giomarelli B, Barnard DL et al. Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J. Virol.84(5), 2511–2521 (2010).
- Larson RA, Dai D, Hosack VT et al. Identification of a broad-spectrum arenavirus entry inhibitor. J. Virol.82(21), 10768–10775 (2008).
- Altmann SE, Jones JC, Schultz-Cherry S, Brandt CR. Inhibition of vaccinia virus entry by a broad spectrum antiviral peptide. Virology388(2), 248–259 (2009).
- Jones JC, Turpin EA, Bultmann H, Brandt CR, Schultz-Cherry S. Inhibition of influenza virus infection by a novel antiviral peptide that targets viral attachment to cells. J. Virol.80(24), 11960–11967 (2006).
- Song JM, Lee KH, Seong BL. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res.68(2), 66–74 (2005).
- Song JM, Park KD, Lee KH et al. Biological evaluation of anti-influenza viral activity of semi-synthetic catechin derivatives. Antiviral Res.76(2), 178–185 (2007).
- Leikina E, Delanoe-Ayari H, Melikov K et al. Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat. Immunol.6(10), 995–1001 (2005).
- Kotwal GJ, Kaczmarek JN, Leivers S et al. Anti-HIV, anti-poxvirus, and anti-SARS activity of a nontoxic, acidic plant extract from the Trifollium species Secomet-V/anti-vac suggests that it contains a novel broad-spectrum antiviral. Ann. NY Acad. Sci.1056, 293–302 (2005).
- Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N. Engl. J. Med.321(25), 1696–1702 (1989).